131 related articles for article (PubMed ID: 30173294)
21. Epigenetics of Cutaneous T-Cell Lymphomas.
Hara N; Sawada Y
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408897
[TBL] [Abstract][Full Text] [Related]
22. Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells.
Chebly A; Prochazkova-Carlotti M; Idrissi Y; Bresson-Bepoldin L; Poglio S; Farra C; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Front Oncol; 2021; 11():775253. PubMed ID: 34765562
[TBL] [Abstract][Full Text] [Related]
23. Post-translational Lysine Ac(et)ylation in Bacteria: A Biochemical, Structural, and Synthetic Biological Perspective.
Lammers M
Front Microbiol; 2021; 12():757179. PubMed ID: 34721364
[TBL] [Abstract][Full Text] [Related]
24. Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas.
Sugaya M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681738
[TBL] [Abstract][Full Text] [Related]
25. PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma.
Liu F; Gao Y; Xu B; Xiong S; Yi S; Sun J; Chen Z; Liu X; Li Y; Lin Y; Wen Y; Qin Y; Yang S; Li H; Tejasvi T; Tsoi L; Tu P; Ren X; Wang Y
Blood; 2022 Jan; 139(4):554-571. PubMed ID: 34582557
[TBL] [Abstract][Full Text] [Related]
26. Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease.
Zawit M; Bahaj W; Gurnari C; Maciejewski J
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503230
[TBL] [Abstract][Full Text] [Related]
27. Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma.
Zhang P; Zhang M
Front Oncol; 2021; 11():663961. PubMed ID: 34249700
[TBL] [Abstract][Full Text] [Related]
28. R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin.
Safari M; Litman T; Robey RW; Aguilera A; Chakraborty AR; Reinhold WC; Basseville A; Petrukhin L; Scotto L; O'Connor OA; Pommier Y; Fojo AT; Bates SE
Mol Cancer Res; 2021 Aug; 19(8):1361-1374. PubMed ID: 34050002
[TBL] [Abstract][Full Text] [Related]
29. Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy.
García-Díaz N; Piris MÁ; Ortiz-Romero PL; Vaqué JP
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923722
[TBL] [Abstract][Full Text] [Related]
30. Impact of a case-based collaborative learning curriculum on knowledge and learning preferences of dermatology residents.
Said JT; Thompson LL; Foord L; Chen ST
Int J Womens Dermatol; 2020 Dec; 6(5):404-408. PubMed ID: 33898708
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.
Bobrowicz M; Slusarczyk A; Domagala J; Dwojak M; Ignatova D; Chang YT; Iselin C; Miazek-Zapala N; Marhelava K; Guenova E; Winiarska M
Oncol Lett; 2020 Jul; 20(1):533-540. PubMed ID: 32565979
[TBL] [Abstract][Full Text] [Related]
32. Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma.
Iyer A; Hennessey D; O'Keefe S; Patterson J; Wang W; Wong GK; Gniadecki R
Blood Adv; 2020 Jun; 4(11):2489-2500. PubMed ID: 32502269
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.
Gluud M; Willerslev-Olsen A; Gjerdrum LMR; Lindahl LM; Buus TB; Andersen MH; Bonefeld CM; Krejsgaard T; Litvinov IV; Iversen L; Becker JC; Persson JL; Koralov SB; Litman T; Geisler C; Woetmann A; Odum N
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32414221
[TBL] [Abstract][Full Text] [Related]
34. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.
Martinez XU; Di Raimondo C; Abdulla FR; Zain J; Rosen ST; Querfeld C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):239-252. PubMed ID: 31585624
[TBL] [Abstract][Full Text] [Related]
35. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
36. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
Oka T; Miyagaki T
Front Med (Lausanne); 2019; 6():116. PubMed ID: 31192214
[TBL] [Abstract][Full Text] [Related]
37. Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.
Wobser M; Weber A; Glunz A; Tauch S; Seitz K; Butelmann T; Hesbacher S; Goebeler M; Bartz R; Kohlhof H; Schrama D; Houben R
J Hematol Oncol; 2019 Mar; 12(1):30. PubMed ID: 30885250
[TBL] [Abstract][Full Text] [Related]
38. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
Lopez AT; Bates S; Geskin L
Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
[TBL] [Abstract][Full Text] [Related]
39. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Trager MH; Geskin LJ
G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
[TBL] [Abstract][Full Text] [Related]
40. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
